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SCIENTIFIC EDITORIAL
Optimal  duration  of  dual  antiplatelet  therapy  after
drug-eluting  stent  implantation
Durée  optimale  de  la  bithérapie  anti-agrégante  plaquettaire  après  stent  actif
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Drug-eluting  stents  (DES)  have  become  the  standard  in  percutaneous  coronary  revascula-
rization.  Several  pivotal  clinical  trials  have  shown  that,  compared  with  a bare-metal  stent
(BMS),  the  DES  is  associated  with  signiﬁcant  reductions  in  the  risk  of  restenosis  and  the  need
for  target-lesion  revascularization  [1,2].  Drug-eluting  stents  are  currently  recommended
as  the  ﬁrst-choice  option,  especially  when  the  risk  of  restenosis  is  high  (i.e.  in  patients
with  diabetes,  long  lesions,  chronic  total  occlusion,  bifurcation  lesions,  restenotic  lesions,
small  vessels).  According  to  the  latest  guidelines  on  patients  presenting  with  ST-segment
elevation,  if  the  patient  has  no  contraindications  to  prolonged  dual  antiplatelet  therapy
(DAPT)  (such  as  an  indication  for  oral  anticoagulation  or  estimated  high  long-term  bleeding
risk)  and  is  likely  to  be  compliant,  DES  should  be  preferred  over  BMS  (class  IIa,  level  A)  [3].
The  combination  of  aspirin  and  an  adenosine  diphosphate-receptor  blocker  such  as
clopidogrel,  prasugrel  or  ticagrelor  is  mandatory  after  percutaneous  coronary  intervention
(PCI).  Usually,  this  DAPT  includes  aspirin  75—100  mg/day  per  os  plus  clopidogrel  75  mg/day.
But,  the  optimal  duration  of  DAPT  after  DES  insertion  is  still  debated.  For  example,  the
recommendations  put  forward  by  the  American  College  of  Cardiology/American  HeartProcédure  coronaire
interventionnelle  ;
Recommandations  ;
Étude  randomisée
Association  (AHA/ACCA)  and  those  from  the  European  Society  of  Cardiology  (ESC)  diverge
slightly.  According  to  the  AHA/ACCA,  in  addition  to  aspirin,  clopidogrel  therapy  should
be  continued  for  at  least  12  months  after  DES  implantation,  whereas  the  ESC  guidelines
recommend  continuation  for  6—12  months  [4,5].
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The  main  reason  why  an  extended  combination  of
APT  therapy  has  been  advocated  is  because  early  dis-
ontinuation  of  DAPT  has  been  identiﬁed  as  a  risk  factor
or  late  stent  thrombosis  in  patients  with  a  DES  [6].  It
as  suggested  that  some  late  clinical  events  that  occur
ater  than  1  year  after  DES  implantation  may  be  due  to
elayed  arterial  healing  after  implantation  of  DES.  In  the
bsence  of  randomized  data,  two  independent  observational
egistries  have  largely  inﬂuenced  the  current  recommen-
ation  to  prolong  clopidogrel  therapy  for  ≥  12  months  or
or  6—12  months  after  DES  implantation  [7,8].  The  BASKET-
ATE  trial  reported  a  >  70%  increase  in  rates  of  death  or
yocardial  infarction  in  DES  recipients  who  discontinued
lopidogrel  at  6  months  compared  with  patients  treated
ith  BMS  [7].  Similarly,  a  50%  increase  in  rates  of  all-
ause  death  or  myocardial  infarction  was  observed  in
he  Duke  Heart  Center  registry  in  patients  treated  with
ES  who  discontinued  clopidogrel  at  6  months  compared
ith  those  who  continued  the  treatment  for  24  months
8].  However,  prolonged  DAPT  has  been  associated  with
igher  severe  bleeding  rates  compared  with  aspirin  ther-
py  alone:  reported  incidences  of  major  bleeding  ranged
rom  1.8%  to  3.7%  and  from  1.7%  to  5.1%  for  minor  bleed-
ng.
The  question  on  the  optimal  duration  of  DAPT  after  DES
s  not  only  theoretical.  More  than  60,000  patients  in  France
eceive  a  DES  every  year.  For  each  patient,  the  clinician  has
o  make  a  decision.  It  is  not  surprising  therefore  that  large
linical  trials  have  been  undertaken.  Owing  to  the  large
umber  of  DES  implantations  worldwide,  the  optimization  of
APT  is  important  for  both  patient  recovery  and  economic
fﬁciency.
Recently,  the  results  from  four  trials  have  suggested  the
ossibility  that  a  shorter  duration  of  DAPT  may  be  sufﬁcient
fter  DES  implantation.  The  ﬁrst  randomized  study  on  this
ssue  analysed  combined  data  from  two  multicentre  trials:
he  REAL-LATE  and  ZEST-LATE  trials  [9].  This  study  found
o  signiﬁcant  beneﬁt  associated  with  continuing  clopido-
rel  plus  aspirin  beyond  12  months  after  DES  implantation.
o  reduction  in  the  incidence  of  myocardial  infarction  or
eath  from  cardiac  causes  was  found.  Moreover,  the  rates  of
omposite  outcomes  (myocardial  infarction,  stroke,  death)
ere  higher  with  clopidogrel  plus  aspirin  than  with  aspirin
lone,  although  the  difference  was  not  statistically  signiﬁ-
ant.
The  results  from  the  EXCELLENT  study  showed  that,  at
2  months  after  DES  implantation,  patients  treated  with
2  months  or  6  months  of  DAPT  showed  similar  risks  for
arget  vessel  failure,  deﬁned  as  the  composite  of  cardiac
eath,  myocardial  infarction  and  ischaemia-driven  target
essel  revascularization  [10].  However,  the  non-inferiority
argin  was  wide,  and  the  study  was  underpowered  for
eath  and  myocardial  infarction.  Another  study  has  shown
hat  24  months  of  clopidogrel  therapy  in  patients  with  DES
r  BMS  was  no  more  effective  than  a  6-month  clopido-
rel  regimen  for  reducing  the  composite  endpoint  of  death,
yocardial  infarction  and  cerebrovascular  accident  [11].  In
hat  study,  2  years  of  clopidogrel  therapy  resulted  in  an
ncrease  in  bleeding  episodes.  The  fourth  study,  the  RESET
rial,  compared  3  months  of  DAPT  following  zotarolimus-
luting  stent  implantation  and  12  months  of  DAPT  following
he  other  DES  implantation.  The  investigators  concluded
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hat  the  ﬁrst  strategy  was  non-inferior  to  standard  therapy
12].
These  four  studies  are  interesting  and  could  provide
 paradigm  shift  in  the  management  of  DAPT  after  DES
mplantation.  Interestingly,  none  of  these  studies  investi-
ated  the  same  course  of  DAPT  duration:  12  months  versus
4  months  for  LATE,  6  months  versus  12  months  for  EXCEL-
ENT,  6  months  versus  24  months  for  PRODIGY,  and  3  months
ersus  12  months  for  RESET.  These  data  suggest  the  possibil-
ty  that  a  shorter  duration  of  DAPT  may  be  sufﬁcient  after
mplantation  of  new  generation  DES.  They  do  not  rule  out
he  possibility  that  prolonging  the  clopidogrel  plus  aspirin
reatment  might  result  in  a  reduction  of  major  adverse  car-
iac  events.  As  stated  by  the  authors  themselves,  the  studies
ere  limited  by  a  short  follow-up  and  the  exclusion  of  very
igh-risk  patients.
Importantly,  other  clinical  trials  are  currently  ongoing
o  investigate  optimal  treatment  duration  after  DES  inser-
ion.  The  DAPT  study  aims  to  compare  the  beneﬁts  and
isks  of  12  months  versus  30  months  of  DAPT  in  patients
ndergoing  PCI,  and  it  has  the  largest  number  of  sub-
ects  enrolled  to  date.  Over  20,000  subjects  have  been
nrolled  at  approximately  220  international  clinical  study
ites.  Most  of  the  patients  (>  15,000)  have  received  a  DES.
nterestingly,  in  that  prolonged  combined  antiplatelet  ther-
py,  patients  receive  either  clopidogrel  or  prasugrel,  a  new
hienopyridine.  Another  ongoing  trial  (ISAR-SAFE)  aims  to
ssess  whether  discontinuation  of  clopidogrel  plus  aspirin
t  6  months  after  DES  implantation  is  non-inferior  to  rou-
ine  1-year  treatment.  Not  surprisingly,  French  trials  have
lso  investigated  this  important  question,  including  ARC-
IC,  ITALIC  and  OPTIDUAL  [13]. It  would,  however,  probably
ave  been  wiser  to  perform  one  large  trial  rather  than  three
maller  ones.
In patients  at  high  risk  of  bleeding,  the  LEADERS  FREE  trial
ill  assess  the  shortest  course  of  DAPT  ever  used  (1  month)
ith  an  active  stent  devoid  of  polymer.
Before  appealing  for  a  reduction  in  the  duration  of
APT  after  DES  implantation,  and  while  awaiting  the
esults  of  the  ongoing  trials,  it  has  to  be  kept  in  mind
hat  few  patients  with  an  acute  coronary  syndrome  have
een  included  in  these  four  clinical  trials.  In  patients
ith  an  acute  coronary  syndrome,  pending  the  results
f  ongoing  trials,  9—12  months  of  DAPT  is  recommended,
ith  a  strict  minimum  of  1  month  for  patients  who  have
eceived  a BMS  and  6  months  for  those  with  a  DES
1].
In  conclusion,  according  to  recent  studies,  a  shorter
ourse  of  DAPT  than  recommended  by  the  guidelines  may
e  considered,  especially  with  new-generation  everolimus
nd  zotarolimus  DES,  polymer-free  DES,  and  polymer-
iodegradable  DES,  in  the  absence  of  ACS  at  the  time  of
mplantation.  On  the  other  hand,  no  sound  evidence  is  avail-
ble  to  support  prolongation  of  DAPT  beyond  12  months,
lthough  such  a  strategy  may  be  considered  in  speciﬁc
atient  subsets  (e.g.  those  with  left  main  disease  or  the
ast  remaining  vessel  stenting  receiving  DES).  Lastly,  it
emains  very  important  to  inform  patients  and  their  physi-
ians  about  the  need  to  avoid  premature  discontinuation
f  DAPT.  In  the  meantime,  it  is  not  unreasonable  to  await
he  results  of  ongoing  trials  before  changing  our  prac-
ice.
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